lf 1695 has been researched along with 5,8,11,14-eicosatetraynoic acid in 1 studies
*5,8,11,14-Eicosatetraynoic Acid: A 20-carbon unsaturated fatty acid containing 4 alkyne bonds. It inhibits the enzymatic conversion of arachidonic acid to prostaglandins E(2) and F(2a). [MeSH]
*5,8,11,14-Eicosatetraynoic Acid: A 20-carbon unsaturated fatty acid containing 4 alkyne bonds. It inhibits the enzymatic conversion of arachidonic acid to prostaglandins E(2) and F(2a). [MeSH]
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chap, H; Douste-Blazy, L; Hullin, F; Pascal, M; Ragab-Thomas, JM; Sepulchre, C | 1 |
1 other study(ies) available for lf 1695 and 5,8,11,14-eicosatetraynoic acid
Article | Year |
---|---|
Stimulation of 12-HETE production in human platelets by an immunomodulator, LF 1695. Evidence for activation of arachidonate liberation coupled to cyclo-oxygenase inhibition.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; 5,8,11,14-Eicosatetraynoic Acid; Adjuvants, Immunologic; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; Calcimycin; Cyclooxygenase Inhibitors; Humans; Hydroxyeicosatetraenoic Acids; In Vitro Techniques; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombin | 1989 |